Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04662086 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT04662086: Completed Phase 2 study, sponsored by Stanford University.
NCT04662086 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04662086, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization. The overall hypothesis is that through an adaptive trial design, potential effective therapies (single and combination) may be identified for this group of patients. COVID-19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform protocol designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding (Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the platform, every investigational product will collect data for both Domain primary endpoints. Individual treatments to be evaluated in the platform will be described in separate sub-protocols.
Interventions
- DRUG Acebilustat
- DRUG Camostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2021-04-23 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04662086
The ClinicalTrials.gov registry entry for NCT04662086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acebilustat is the first listed.
NCT04662086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04662086 about?
NCT04662086 is a clinical study titled "COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol". The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization. The overall hypothesis is that through an adaptive trial design, potential ...
What is the current status of trial NCT04662086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2021-04-23. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT04662086?
The interventions under investigation include: Acebilustat (DRUG), Camostat (DRUG).
Who is sponsoring clinical trial NCT04662086?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.